Stuart M. Grant Purchases 5,000 Shares of Eyenovia Inc (NASDAQ:EYEN) Stock

Eyenovia Inc (NASDAQ:EYEN) major shareholder Stuart M. Grant bought 5,000 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were bought at an average price of $3.33 per share, with a total value of $16,650.00. Following the completion of the transaction, the insider now owns 2,226,183 shares in the company, valued at approximately $7,413,189.39. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

NASDAQ:EYEN opened at $2.75 on Tuesday. The stock has a fifty day moving average price of $3.14 and a 200-day moving average price of $3.91. Eyenovia Inc has a fifty-two week low of $2.40 and a fifty-two week high of $6.98.

Eyenovia (NASDAQ:EYEN) last released its earnings results on Wednesday, November 13th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.05. On average, research analysts expect that Eyenovia Inc will post -1.51 earnings per share for the current year.

An institutional investor recently raised its position in Eyenovia stock. Uniplan Investment Counsel Inc. increased its holdings in shares of Eyenovia Inc (NASDAQ:EYEN) by 22.4% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 544,896 shares of the company’s stock after buying an additional 99,896 shares during the quarter. Uniplan Investment Counsel Inc. owned 3.31% of Eyenovia worth $2,343,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.80% of the company’s stock.

EYEN has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Eyenovia in a research report on Friday. Zacks Investment Research upgraded Eyenovia from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a research report on Friday, August 16th. Finally, ValuEngine downgraded Eyenovia from a “buy” rating to a “hold” rating in a research report on Thursday, November 14th.

Eyenovia Company Profile

Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.

Featured Story: Support Level

Insider Buying and Selling by Quarter for Eyenovia (NASDAQ:EYEN)

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.